Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2013. The report details a specific share repurchase transaction executed on September 11, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,182,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,621.00 pence per share; lowest price paid was 1,599.50 pence per share.
- Treasury Holdings (Settled): 517,760,412 shares (9.56% of total issued share capital).
- Treasury Holdings (Including Unsettled): 518,942,412 shares (10.60% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,896,191,510 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,182,000 shares on September 11, 2013. These shares are intended to be held in Treasury. The filing notes that the number of shares in issue (excluding treasury shares) serves as the denominator for shareholder notification calculations under the Financial Conduct Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, future outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (517,760,412 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights held in Treasury (10.60% including unsettled shares).
- Check the total number of shares in issue excluding treasury shares (4,896,191,510) for accurate EPS and ownership percentage calculations.
- Review the price range paid (1,599.50 to 1,621.00 pence) to assess the cost of capital reduction relative to market prices on September 11, 2013.